Trials / Completed
CompletedNCT02541942
Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept™2 Trial
Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept 2 Trial
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- Male
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
This study is conducted globally. This study describes pharmacogenetic testing of saliva samples from patients who participated in the NN1731-3562 trial (adept™2) (NCT01392547). The objective is to determine the HLA (human leukocyte antigen) type and polymorphisms in the FVII gene in patients previously exposed to rFVIIa analogue.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | No treatment given | For patient convenience, genetic material will be collected in the form of saliva samples. |
Timeline
- Start date
- 2015-04-03
- Primary completion
- 2016-04-15
- Completion
- 2016-04-15
- First posted
- 2015-09-04
- Last updated
- 2019-01-04
- Results posted
- 2019-01-04
Locations
15 sites across 7 countries: United States, Greece, Japan, Malaysia, Romania, Serbia, Thailand
Source: ClinicalTrials.gov record NCT02541942. Inclusion in this directory is not an endorsement.